NASDAQ
Medpace Holdings, Inc. (MEDP)
♥ 362 Thanks from members
Medpace Holdings, Inc. (MEDP) demonstrates robust double-digit revenue and earnings growth backed by solid Q2 2026 performance, though investors remain divided over premium valuations, cancellation risks in oncology and cardiovascular trials, and small biopharma sector pressures.